WNT-Pathway Medulloblastoma: What Constitutes Low-Risk and How Low Can One Go? | Oncotarget скачать в хорошем качестве

WNT-Pathway Medulloblastoma: What Constitutes Low-Risk and How Low Can One Go? | Oncotarget

Oncotarget published this research perspective in Volume 14, entitled, “WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?" by researchers from the Department of Radiation Oncology, ACTREC/TMH, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra 410210, India; Department of Neuro-Oncology Laboratory, ACTREC/TMH, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra 410210, India; Department of Pathology, ACTREC/TMH, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra 410210, India; Department of Pediatric Oncology, ACTREC/TMH, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra 410210, India. #openaccess #research #openscience #peerreview #journal #publication #perspective #cancer #oncologyresearch #patients #brain DOI - https://doi.org/10.18632/oncotarget.2... Correspondence to - Tejpal Gupta - [email protected] Abstract Novel biological insights have established that medulloblastoma is a heterogenous disease comprising four broad molecular subgroups - WNT, SHH, Group 3, and Group 4 respectively, resulting in the incorporation of molecular/genetic information in 5th edition of WHO classification and contemporary risk-stratification. Concerns regarding therapy-related late toxicity in long-term survivors have led to systematic attempts at treatment de-intensification in good-risk medulloblastoma. Given the excellent survival (greater than 90%) of WNT-pathway medulloblastoma, prospective clinical trials have focused on optimization of therapy to balance survival versus quality of survival. The currently accepted definition of low-risk WNT-pathway medulloblastoma includes children less than 16 years of age with residual tumour less than 1.5 cm2 and no evidence of metastases. This systematically excludes adolescents and young adults who have been perceived to have worse outcomes. We have previously reported long-term survival of our adolescent and young adult cohort that were largely comparable to childhood medulloblastoma. We now report on molecularly characterized WNT-subgroup patients treated between 2004–2020 with risk-stratified multi-modality therapy to identify differences between childhood (less than 15 years) versus adolescent and young adults (greater than 15 years). Despite modest differences in disease status at presentation and treatment modality, there were no significant differences in patterns of failure or survival between childhood versus adolescent and young adult WNT-pathway medulloblastoma. Two de-intensification trials in low-risk WNT-pathway medulloblastoma – first testing omission of upfront craniospinal irradiation and second a primary chemotherapy approach after surgery – had to be terminated prematurely due to unacceptably high relapse rates suggesting that craniospinal irradiation remains an integral component of treatment. The presence of TP53 mutations and OTX2 gains have recently been reported as independent negative prognostic factors in a multi-institutional cohort of WNT-pathway medulloblastoma raising questions on eligibility of such patients for de-escalation trials. The definition of low-risk WNT-pathway medulloblastoma may need to be refined in light of recent clinical data and newer biological information. Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/deta... Keywords - de-intensification, medulloblastoma, molecular, survival, toxicity About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud -   / oncotarget   Facebook -   / oncotarget   Twitter -   / oncotarget   Instagram -   / oncotargetjrnl   YouTube -    / @oncotargetjournal   LinkedIn -   / oncotarget   Pinterest -   / oncotarget   Reddit -   / oncotarget   Media Contact [email protected] 18009220957